GTBP (GT Biopharma) Marketable Securities : $0.00 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is GT Biopharma Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. GT Biopharma's Marketable Securities for the quarter that ended in Sep. 2024 was $0.00 Mil.

GT Biopharma's annual Marketable Securities declined from Dec. 2021 ($23.01 Mil) to Dec. 2022 ($10.84 Mil) but then increased from Dec. 2022 ($10.84 Mil) to Dec. 2023 ($12.89 Mil).

GT Biopharma Marketable Securities Historical Data

The historical data trend for GT Biopharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GT Biopharma Marketable Securities Chart

GT Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

23.01

10.84

12.89

GT Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Marketable Securities	Get a 7-Day Free Trial															13.37	12.89	7.86	-	-

GT Biopharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

GT Biopharma (NAS:GTBP) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

GT Biopharma Marketable Securities Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

GT Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005

Website

https://www.gtbiopharma.com

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Executives

Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen	director, officer: Exec. Chair. and Interim CEO	LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri	officer: CFO & Secretary	2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel	director	70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk	officer: Pres. of R&D, CMO	HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md	director	157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban	director	1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy	officer: Acting Chief Financial Officer	8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon	director, officer: CFO	7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross	director, officer: Chief Executive Officer	1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski	officer: Chief Medical Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith	director, 10 percent owner, officer: CEO	1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman	10 percent owner	224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc	10 percent owner
Bristol Investment Fund Ltd	10 percent owner	89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205